Herceptin | search
Click here to view Herceptin news from 60+ newspapers.
Bookmark or Share- Herceptin® (trastuzumab) Dosing in HER2+ Adjuvant Breast CancerOne week following the last weekly dose of Herceptin, administer Herceptin at 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks As a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
- herceptin - HER2+ Breast & Stomach Cancer Treatment OptionHerceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes ...
- Herceptin Treatment ScheduleRead about the treatment schedule for Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information. For US Healthcare Professionals
- Potential Side Effects of HerceptinLearn about potential side effects when using Herceptin® (trastuzumab) as a HER2+ metastatic breast cancer treatment. Read the Important Safety Information (ISI) for Herceptin® (trastuzumab). See full safety & Boxed Warnings for more information.
- Preparing for Treatment for HER2+ Early Breast Cancer - herceptinFind information about preparing for Herceptin® (trastuzumab) infusion treatment for HER2+ early breast cancer. See full safety & Boxed Warnings for more information.
More
